Thanks for your question. You can find XBB.1.5.10 by following the link below. You can zoom in on the red circles. XBB.1.5 will be green dots, and XBB.1.5.10 is highlighted red. Click on dots to pull up data on sequenced cases.
Here is another link to this variants info, with estimated cases, growth advantage etc. As of now, only in North and South Carolina but the majority of those sequenced have been in North Carolina.
Keep in mind that the growth advantage is an estimate and changes as more data becomes available. Now it's saying over 100% growth advantage but it will fluctuate.
It isn't as clear whether XBB.1.5.10 has a strong enough advantage or what that advantage is yet. XBB.1.5 was obviously going to take over. The most likely candidate to surpass XBB.1.5.10 is XBB.1.9.1. XBB.1.9.1 has a head start on XBB.1.5.10 so it looks like XBB.1.5.10 won't survive long unless it mutates more .
The dangerous trend is the changes occurring in the body of the virus. It appears to be trying to further suppress the last line of defense. The T-cell response. That's likely the path XBB.1.9.1 is on but still to early to say for sure. If that is the case, then it won't be good for humans. As is, these variants are much better at suppressing the immune response and persisting. Weakening immune systems, and increasing odds of autoimmune disorders, cancers and vascular dysfunction.
Where are you getting this 80% increase figure from? There's not even an XBB.1.5.10 on the chart you linked to. I only see it in your first graphic.
Thanks for your question. You can find XBB.1.5.10 by following the link below. You can zoom in on the red circles. XBB.1.5 will be green dots, and XBB.1.5.10 is highlighted red. Click on dots to pull up data on sequenced cases.
https://cov2tree.org/?color=%7B"field"%3A"meta_pango_lineage_usher"%7D&srch=%5B%7B"key"%3A"search3"%2C"type"%3A"meta_pango_lineage_usher"%2C"method"%3A"text_exact"%2C"text"%3A"XBB.1.5.10"%2C"new_residue"%3A"any"%2C"position"%3A484%2C"min_tips"%3A0%2C"gene"%3A"S"%7D%5D&enabled=%7B"search3"%3Atrue%7D
Thanks!
Here is another link to this variants info, with estimated cases, growth advantage etc. As of now, only in North and South Carolina but the majority of those sequenced have been in North Carolina.
Keep in mind that the growth advantage is an estimate and changes as more data becomes available. Now it's saying over 100% growth advantage but it will fluctuate.
https://cov-spectrum.org/explore/United%20States/AllSamples/Past6M/variants?aaMutations=Orf1b%3AA1643V%2CS%3AF456L&nextcladePangoLineage=XBB.1.5*
Awesome resource, thank you again!
If you know, how did XBB.1.5 compare in its early stages to this one? Was just curious.
It isn't as clear whether XBB.1.5.10 has a strong enough advantage or what that advantage is yet. XBB.1.5 was obviously going to take over. The most likely candidate to surpass XBB.1.5.10 is XBB.1.9.1. XBB.1.9.1 has a head start on XBB.1.5.10 so it looks like XBB.1.5.10 won't survive long unless it mutates more .
The dangerous trend is the changes occurring in the body of the virus. It appears to be trying to further suppress the last line of defense. The T-cell response. That's likely the path XBB.1.9.1 is on but still to early to say for sure. If that is the case, then it won't be good for humans. As is, these variants are much better at suppressing the immune response and persisting. Weakening immune systems, and increasing odds of autoimmune disorders, cancers and vascular dysfunction.